Limits...
A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging.

Wang Y, Lin T, Zhang W, Jiang Y, Jin H, He H, Yang VC, Chen Y, Huang Y - Theranostics (2015)

Bottom Line: As a case in point, expression of matrix metalloproteases (MMP) is significantly up-regulated in tumorigenesis, invasion, and metastasis among a majority of cancers.The T7-functionalized nanoprobe is capable of detecting the orthotopic brain tumor, with clear, real-time in vivo imaging.This method is promising for in vivo detection of brain tumor, and real-time monitor of a TAP (i.e., MMP-2).

View Article: PubMed Central - PubMed

Affiliation: 1. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. ; 2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China.

ABSTRACT
Tumor-associated proteases (TAPs) have been intensively studied because of their critical roles in cancer development. As a case in point, expression of matrix metalloproteases (MMP) is significantly up-regulated in tumorigenesis, invasion, and metastasis among a majority of cancers. Here we present a prodrug-type, MMP-2-responsive nanoprobe system with high efficiency and low toxicity for detecting MMP-2-overexpressed tumors. The nanoprobe system is featured by its self-assembled fabrication and FRET effect. This prodrug-type nanoprobe is selectively activated by MMP-2, and thus useful for detection of the MMP-2-overexpressed cells and tumors. The nanoprobe system works successfully in various animal tumor models, including human fibrosarcoma and subcutaneous glioma xenograft. Furthermore, in order to overcome the blood brain barrier (BBB) and achieve brain tumor targeting, a transferrin-receptor targeting peptide (T7 peptide) is strategically incorporated into the nanoprobe. The T7-functionalized nanoprobe is capable of detecting the orthotopic brain tumor, with clear, real-time in vivo imaging. This method is promising for in vivo detection of brain tumor, and real-time monitor of a TAP (i.e., MMP-2).

No MeSH data available.


Related in: MedlinePlus

In vivo imaging for MCF-7 tumor model with moderate expression of MMP-2. (A) Fluorescence images at various time points after i.v. injection. (B) The radiant efficiency and tumor to normal area ratio in the tumor site. (C) In vivo imaging following intramuscular injection at various time points. (D) The radiant efficiency in the intramuscular injection site.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4440437&req=5

Figure 6: In vivo imaging for MCF-7 tumor model with moderate expression of MMP-2. (A) Fluorescence images at various time points after i.v. injection. (B) The radiant efficiency and tumor to normal area ratio in the tumor site. (C) In vivo imaging following intramuscular injection at various time points. (D) The radiant efficiency in the intramuscular injection site.

Mentions: The nanoprobe was also tested for tumor-associated activation in MCF-7 xenografted tumors. The MCF-7 tumor still could be identified at 1-2 hour post-injection; the activation efficiency was relatively weak yet clearly distinguishable. The fluorescence signal in tumor displayed more than 2-fold higher than that of the adjacent tissue area (Figure 6A&B).


A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging.

Wang Y, Lin T, Zhang W, Jiang Y, Jin H, He H, Yang VC, Chen Y, Huang Y - Theranostics (2015)

In vivo imaging for MCF-7 tumor model with moderate expression of MMP-2. (A) Fluorescence images at various time points after i.v. injection. (B) The radiant efficiency and tumor to normal area ratio in the tumor site. (C) In vivo imaging following intramuscular injection at various time points. (D) The radiant efficiency in the intramuscular injection site.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4440437&req=5

Figure 6: In vivo imaging for MCF-7 tumor model with moderate expression of MMP-2. (A) Fluorescence images at various time points after i.v. injection. (B) The radiant efficiency and tumor to normal area ratio in the tumor site. (C) In vivo imaging following intramuscular injection at various time points. (D) The radiant efficiency in the intramuscular injection site.
Mentions: The nanoprobe was also tested for tumor-associated activation in MCF-7 xenografted tumors. The MCF-7 tumor still could be identified at 1-2 hour post-injection; the activation efficiency was relatively weak yet clearly distinguishable. The fluorescence signal in tumor displayed more than 2-fold higher than that of the adjacent tissue area (Figure 6A&B).

Bottom Line: As a case in point, expression of matrix metalloproteases (MMP) is significantly up-regulated in tumorigenesis, invasion, and metastasis among a majority of cancers.The T7-functionalized nanoprobe is capable of detecting the orthotopic brain tumor, with clear, real-time in vivo imaging.This method is promising for in vivo detection of brain tumor, and real-time monitor of a TAP (i.e., MMP-2).

View Article: PubMed Central - PubMed

Affiliation: 1. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China. ; 2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China.

ABSTRACT
Tumor-associated proteases (TAPs) have been intensively studied because of their critical roles in cancer development. As a case in point, expression of matrix metalloproteases (MMP) is significantly up-regulated in tumorigenesis, invasion, and metastasis among a majority of cancers. Here we present a prodrug-type, MMP-2-responsive nanoprobe system with high efficiency and low toxicity for detecting MMP-2-overexpressed tumors. The nanoprobe system is featured by its self-assembled fabrication and FRET effect. This prodrug-type nanoprobe is selectively activated by MMP-2, and thus useful for detection of the MMP-2-overexpressed cells and tumors. The nanoprobe system works successfully in various animal tumor models, including human fibrosarcoma and subcutaneous glioma xenograft. Furthermore, in order to overcome the blood brain barrier (BBB) and achieve brain tumor targeting, a transferrin-receptor targeting peptide (T7 peptide) is strategically incorporated into the nanoprobe. The T7-functionalized nanoprobe is capable of detecting the orthotopic brain tumor, with clear, real-time in vivo imaging. This method is promising for in vivo detection of brain tumor, and real-time monitor of a TAP (i.e., MMP-2).

No MeSH data available.


Related in: MedlinePlus